MVZ HPH Brings ctDNA Blood Test for Cancer Monitoring to Europe, Based on Haystack MRD® Technology from Quest Diagnostics®

Original from: PR Newswire

MVZ HPH Institute for Pathology and Hematopathology GmbH, today announced the availability of HPH MRD, a new tumor-informed circulating-tumor DNA (ctDNA) blood test for detecting minimal residual disease (MRD) in patients diagnosed with solid tumor cancers. The HPH MRD test is an in-house test manufactured by HPH that makes use of Haystack MRD technology and is available through a license from Haystack Oncology, a subsidiary of Quest Diagnostics® (NYSE: DGX), which developed and provides the Haystack MRD in-house developed test in the United States. The technology was purpose-built to detect ultralow levels of ctDNA with exceptional sensitivity and specificity, enabling the reliable identification of residual or recurrent disease.

HPH MRD testing will be performed in the company's laboratories in Hamburg, Germany, providing clinicians with potential access to next-generation MRD testing. Local availability will help ensure improved clinical implementation and timely delivery of results. All testing and data will remain with HPH in Germany, facilitating compliance with data protection and regulatory standards while supporting access. The HPH MRD test leverages whole-genome sequencing to analyze a patient's tumor tissue and design individualized patient panels, potentially providing greater insight into ctDNA levels than conventional methods.

"At HPH, our mission is to provide patients and clinicians with the highest quality diagnostic tools to guide personalized cancer care," said Prof. Markus Tiemann, CEO, MVZ HPH Institute for Pathology and Hematopathology GmbH. "By licensing Haystack's groundbreaking MRD technology to develop our own test in our local Hamburg laboratory, we can now offer our patients access to testing that was previously only available abroad, with potentially faster results".

ctDNA MRD testing is rapidly transforming cancer care by detecting molecular evidence of disease and providing insights that often remain undetectable with standard imaging methods. Cancer treatment typically involves surgery followed by chemotherapy or other therapies; however, tiny amounts of cancer can sometimes persist and lead to disease recurrence. By identifying tumor-derived DNA fragments in the bloodstream, ctDNA MRD testing may enable earlier and more accurate detection of residual or recurrent disease—empowering clinicians to make timely, evidence-based treatment decisions with confidence.

"Patients and physicians in Europe have lacked convenient access to the most sensitive MRD technologies, with samples often needing to be shipped internationally," said Dan Edelstein, Vice President & General Manager and a co-founder of Haystack Oncology. "Our licensing agreement with HPH is an important step toward making next-generation MRD testing part of routine care beyond the U.S."

Source: MVZ HPH Brings ctDNA Blood Test for Cancer Monitoring to Europe, Based on Haystack MRD® Technology from Quest Diagnostics®